ArticleHead & neck2025
Adjuvant External Beam Radiotherapy in Differentiated Thyroid Cancers: An Audit of Clinical Practice, Adapting to New Evidence.
Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere is limited evidence on the role of adjuvant external beam radiotherapy in differentiated thyroid cancer (DTC).
methodsWe conducted a retrospective study of patients with DTC treated with adjuvant Intensity Modulated radiotherapy (IMRT) from 2011 to 2024.
resultsFifty-nine patients were analyzed with median follow-up of 53 months. All the patients had undergone total thyroidectomy. Gross extrathyroidal extension was seen in 76% of patients, while 54% had R1/R2 resection. High-risk histological types were seen in 51% of patients, while 34% had recurrent disease. The 5-year locoregional control (LRC) was 89.3% while 5-year overall survival (OS) was 84.6%. Acute Grade 3 dermatitis and dysphagia were seen in 12% and 10%, respectively. Late toxicity, including tracheostomy placement and feeding tube dependence, was seen in three and one patient, respectively.
conclusionAdjuvant IMRT in patients with DTC with high risk of locoregional recurrence resulted in good LRC with acceptable toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.